[1] Reardon LC, Lin JP, VanArsdell GS, et al: Orthotopic Heart and Combined Heart Liver Transplantation: the Ultimate Treatment Option for Failing Fontan Physiology. Curr Transplant Rep, 2021, 8(1):9-20.
[2] Montano-Loza AJ, Rodriguez-Peralvarez ML, Pageaux GP, et al. Liver transplantation immunology: Immunosuppression, rejection, and immunomodulation. J Hepatol, 2023, 78(6):1199-1215.
[3] Markus MR, Baumeister SE, Stritzke J, et al. Hepatic steatosis is associated with aortic valve sclerosis in the general population: the Study of Health in Pomerania (SHIP). Arterioscler Thromb Vasc Biol,2013, 33(7):1690-1695.
[4] Izzy M, Soldatova A, Sun X, et al. Cirrhotic Cardiomyopathy Predicts Posttransplant Cardiovascular Disease: Revelations of the New Diagnostic Criteria. Liver Transpl, 2021, 27(6):876-886.
[5] Lai JC, Covinsky KE, McCulloch CE, et al. The Liver Frailty Index Improves Mortality Prediction of the Subjective Clinician Assessment in Patients With Cirrhosis. Am J Gastroenterol, 2018, 113(2):235-242.
[6] Sundaram V, Mahmud N, Perricone G, et al: Longterm Outcomes of Patients Undergoing Liver Transplantation for Acute-on-Chronic Liver Failure. Liver Transpl, 2020, 26(12):1594-1602.
[7] Mathurin P, Lucey MR. Liver transplantation in patients with alcohol-related liver disease: current status and future directions. Lancet Gastroenterol Hepatol, 2020, 5(5):507-514.
[8] Serenari M, Cappelli A, Cucchetti A, et al: Deceased Donor Liver Transplantation After Radioembolization for Hepatocellular Carcinoma and Portal Vein Tumoral Thrombosis: A Pilot Study. Liver Transpl, 2021, 27(12):1758-1766.
[9] 宋方彬, 李善宝, 徐军明. 肝移植治疗肝内胆管癌的现状与挑战. 肝脏, 2022, 27(5):514-515,520.
[10] Mazzaferro V, Pulvirenti A, Coppa J. Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation? J Hepatol, 2007, 47(4):460-466.
[11] Sposito C, Rossi RE, Monteleone M, et al. Postrecurrence Survival After Liver Transplantation for Liver Metastases From Neuroendocrine Tumors. Transplantation,2021, 105(12):2579-2586.
[12] Kasahara M, Sakamoto S, Fukuda A, et al: Marginal parental donors for pediatric living donor liver transplantation. Curr Opin Organ Transplant.?2022, 27(4):346-350.
[13] European Association for the Study of the Liver.? EASL Clinical Practice Guidelines on the management of cystic liver diseases. J Hepatol, 2022, 77(4):1083-1108.
[14] Thuong M, Ruiz A, Evrard P, et al. New classification of donation after circulatory death donors definitions and terminology. Transpl Int, 2016, 29(7):749-759.
[15] Croome KP, Mathur AK, Aqel B, et al. Classification of Distinct Patterns of Ischemic Cholangiopathy Following DCD Liver Transplantation: Distinct Clinical Courses and Long-term Outcomes From a Multicenter Cohort. Transplantation,2022, 106(6):1206-1214.
[16] Sousa Da Silva RX, Weber A, Dutkowski P, et al. Machine perfusion in liver transplantation. Hepatology, 2022, 76(5):1531-1549.
[17] Levitsky J, Feng S. Tolerance in clinical liver transplantation. Hum Immunol,2018, 79(5):283-287.
[18] Kazemi A, Kazemi K, Sami A, et al. Identifying Factors That Affect Patient Survival After Orthotopic Liver Transplant Using Machine-Learning Techniques. Exp Clin Transplant, 2019, 17(6):775-783. |
